ABUS vs TFX · P/E 5.4, rev $6.2M vs P/E 2083, rev $3.05B
Arbutus Biopharma Corp (ABUS) versus Teleflex Incorporated (TFX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Teleflex Incorporated (TFX) is a medical instruments & supplies company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TFX revenue for 2024-12-31 was $3.05B. Net income was $69.7M. Revenue was up 2.4% from 2023-12-31 to 2024-12-31. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
Not investment advice. Open the ABUS and TFX stock pages for the full models.
Not investment advice.